Furthermore, high HER2 expression predicted an unfavorable oncologic outcome, and low CAIX and high ERCC1 expression predicted an unfavorable response to adjuvant treatment in patients with early cervical cancer. This evidence concerns the gene CA9 and cervical cancer.